HealthyNCT07134140
Omega-3 Fatty Acids in Muscle Function and Health
A study testing Omega-3 in people with Healthy, run by European University Cyprus at 1 site in Cyprus.
Trial summary
This study aims to investigate the effects of omega-3 fatty acid supplementation on muscle performance, neuromuscular function, inflammation, and oxidative stress at rest and after eccentric exercise. Read more about this study
- Who is it for?
- Ages 20 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Omega-3
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 32 participants
- Where
- 1 siteCyprus
- Study dates
- Sep 2025to Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Body Mass Index (BMI) within the normal range (18.5-25 kg/m²).
- Healthy individuals without severe medical conditions (e.g., diabetes, coronary artery disease, hypertension, neuromuscular disorders).
- No musculoskeletal injury in the lower limbs (e.g., bone fracture, tendon rupture, grade III muscle strain) within the last 6 months before enrollment.
- Negative responses to all questions on the PAR-Q questionnaire indicating no contraindications to participating in exercise testing.
- Mentally capable of providing informed consent.
Who cannot join
- Use of any pharmaceutical medications (e.g., statins, aspirin, ibuprofen).
- Use of dietary supplements (e.g., protein, vitamins) within the last 3 months before enrollment.
- Participation in a structured training program involving more than three training sessions per week during the study period.
- Following a special diet (e.g., intermittent fasting, ketogenic diet, vegetarian diet).
- Allergy or intolerance to fish oil or olive oil.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Cyprus1 site
European University Cyprus
Nicosia, Engomi, 1516
Anastasios Theodorou, Dr., 22713110, A.Theodorou@euc.ac.cy
About this study
Official title: Effects of Omega-3 Fatty Acid Supplementation on Muscle Performance, Neuromuscular Function, and Inflammation at Rest and Following Eccentric Exercise.
This study aims to investigate the effects of omega-3 fatty acid supplementation on muscle performance, neuromuscular function, inflammation, and oxidative stress at rest and after eccentric exercise. The findings may provide insights into the role of omega-3 fatty acids in muscle function, physiology, and metabolism following muscle-damaging exercise. Additionally, the effects of omega-3 fatty acids on cardiovascular health will be investigated.
Read the detailed description
The study is a double-blind, randomized controlled trial. Two parallel groups of 16 healthy males and females each (sex counterbalanced, 20-45 years) will randomly take 3 g of fish oil [1500 mg EPA (eicosapentaenoic acid) + 750 mg DHA (docosahexaenoic acid), Now Foods, USA] or a placebo (3 g of olive oil) for 12 weeks. Before taking the supplement, participants will perform a unilateral isokinetic eccentric exercise session of maximal voluntary intensity (10 repetitions x 10 sets of knee extensions at a speed of 60 degrees per second). Dominant and non-dominant legs will be allocated equally and randomly across participants. Physiological assessments and blood samples will be collected immediately before exercise and 2 and 4 days after eccentric exercise (bout 1). Then, participants will start the supplementation for 12 weeks. At the end of the supplementation period, participants will perform the same eccentric exercise protocol (bout 2) with their opposite leg. The same assessments and blood sampling will be conducted at the same time points (i.e., immediately before and 2 and 4 days after eccentric exercise).
- Conditions
- Healthy
- Being tested
- Omega-3, Placebo comparator
- Keywords
- omega-3, eccentric exercise, muscle function
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Omega-3Dietary supplement
Participants will take three capsules per day (a total of 1,500 mg EPA and 750 mg DHA). They will take 1 g with each main meal (breakfast, lunch, and dinner).
Placebo comparatorDietary supplement
Participants will take 3 g of olive oil. They will take 1 g with each main meal (breakfast, lunch, and dinner).
| Study group | Role | What they receive |
|---|---|---|
| Omega-3 | Experimental | Participants in this group will take 3 g of fish oil [(NOW, Ultra Omega-3 Fish Oil, (NOW, Bloomingdale, IL, USA)] for 12 weeks. Receives: Dietary Supplement: Omega-3 |
| Placebo | Placebo comparator | Participants in this group will take 3 g of olive oil for 12 weeks. Receives: Dietary Supplement: Placebo comparator |
What is being measured
The primary outcome is the main question the study is designed to answer.
Muscle Strength
Muscle strength of the knee extensors will be measured using an isokinetic dynamometer during maximal voluntary contractions. The unit of measure is Newton-meters (Nm).
Measured: Changes in muscle strength after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Maximal Oxygen Uptake (VO₂ max)
VO₂ max will be assessed during a graded exercise test on a cycle ergometer. The measure unit is milliliters per kilogram of body mass per minute (ml/kg/min).
Measured: Changes in VO₂ max after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle Fatigue Index (MFI)
MFI will be calculated as the percentage decline (%) in peak torque across a series of repeated maximal contractions of the knee extensor muscles on an isokinetic dynamometer.
Measured: Changes in MFI after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle Oxygenation
Muscle oxygenation will be measured in the vastus lateralis using near-infrared spectroscopy (NIRS). Parameters include oxyhemoglobin (O₂Hb), deoxyhemoglobin (HHb), and total hemoglobin levels, which will be expressed in arbitrary units (AU).
Measured: Changes in muscle oxygenation after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Creatine Kinase
Creatine kinase activity will be measured in International Units (IU) via the enzymatic colorimetric method in fasting plasma samples.
Measured: Change in creatine kinase activity after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Range of Motion (ROM)
ROM of the knee joint will be measured in degrees (°) using an isokinetic dynamometer, with full extension defined as 0° and flexion recorded up to 120°.
Measured: Change in ROM after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle Thickness
Muscle thickness of the vastus lateralis will be measured using B-mode ultrasound with a linear probe, in millimeters (mm).
Measured: Change in muscle thickness after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Echo Intensity
Echo intensity of the vastus lateralis will be assessed using B-mode ultrasound with a linear probe and quantified from grayscale image analysis, expressed in arbitrary units (0-255).
Measured: Change in echo intensity after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Blood Lipids Profile
Fasting blood samples will be collected and analyzed to assess the participant's lipid profile, including: Total Cholesterol (TC). Expressed in mg/dL. Low-Density Lipoprotein Cholesterol (LDL-C). Expressed in mg/dL. High-Density Lipoprotein Cholesterol (HDL-C). Expressed in mg/dL. Triglycerides (TG). Expressed in mg/dL. Blood will be drawn after a minimum of 8-12 hours of fasting. Lipid concentrations will be determined using standard enzymatic colorimetric methods on an automated clinical chemistry analyzer.
Measured: Change in blood lipids from baseline (immediately before supplementation) to 12 weeks after the supplementation period.
Secondary outcomes (21)
Omega-3 Index
The Omega-3 Index will be assessed as a biomarker of long-chain omega-3 fatty acid status. It is defined as the combined percentage (%) of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell (RBC) membranes, expressed as a proportion of total identified fatty acids.
Blood samples will be collected following an overnight fast, and red blood cells will be isolated for fatty acid analysis. EPA and DHA levels will be quantified via gas chromatography, and the Omega-3 Index will be reported as a percentage (%).
Measured: Change in omega-3 index in red blood cells from baseline (immediately before supplementation) to 12 weeks after the supplementation period.
Rate of Force Development (RFD).
RFD will be calculated as the slope of the torque-time curve during the early phase of voluntary contraction. It will be measured in Newton-meters per second (Nm/s).
Measured: Change in RFD after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Electromechanical Delay (EMD)
EMD will be defined as the time lag between the onset of electrical activity (via surface EMG) and the onset of force production, measured in milliseconds (ms).
Measured: Change in EMD after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Force Matching Error (FME)
FME will be assessed during a submaximal isometric contraction using an isokinetic dynamometer and expressed as the percentage difference between the target and produced force (%).
Measured: Change in FME after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Joint Position Sense (JPS)
JPS will be evaluated as the absolute angular difference between a target knee joint angle and the participant's reproduced angle, measured in degrees (°) using an isokinetic dynamometer.
Measured: Change in JPS after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Delayed Onset Muscle Soreness (DOMS).
DOMS will be assessed using a 1-10 visual analog scale (VAS), where 1 indicates no pain and 10 indicates extreme pain.
Measured: Change in DOMS after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Countermovement Jump (CMJ)
CMJ will be measured in centimeters (CM) using a force plate.
Measured: Change in CMJ after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Contact Time
Duration of foot contact with the force plate during landing, expressed in milliseconds (ms).
Measured: Change in contact time after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Stability Index
The stability index will be assessed from the center of pressure displacement using a force platform and expressed in millimeters (mm).
Measured: Change in stability index after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
F2-Isoprostanes
F2-Isoprostanes will be quantified as a marker of lipid peroxidation using ELISA and expressed in picograms per milliliter (pg/mL).
Measured: Change in F2-Isoprostanes after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Glutathione
Glutathione will be measured as an indicator of endogenous antioxidant capacity using a colorimetric assay and expressed in micromoles per gram of hemoglobin (μmol/g Hb).
Measured: Change in glutathione after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Protein carbonyls
Protein carbonyls will be measured as a marker of oxidative protein damage using a spectrophotometric assay and expressed in nanomoles per gram of hemoglobin (nmol/g Hb).
Measured: Change in protein carbonyls after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Interleukin-6 (IL-6)
IL-6 will be measured as a marker of inflammation using ELISA and expressed in picograms per milliliter (pg/mL).
Measured: Change in IL-6 after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Tumor Necrosis Factor-alpha (TNF-α)
TNF-α will be measured as a marker of inflammation using ELISA and expressed in picograms per milliliter (pg/mL).
Measured: Change in TNF-α after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Pennation Angle
The pennation angle of the vastus lateralis will be measured under resting conditions using longitudinal B-mode ultrasound imaging and expressed in degrees (°).
Measured: Change in pennation angle after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Fascicle Length
Fascicle length of the vastus lateralis will be determined under resting condition from B-mode ultrasound images, either measured directly from visible fascicles or estimated using trigonometric calculations, and expressed in millimeters
Measured: Change in fascile length after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle Stiffness
Muscle stiffness, reflecting the resistance of the muscle to an external force, will be measured and expressed in newtons per meter (N/m) using the Myoton Pro device.
Measured: Change in muscle stifness after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle Tone
Muscle tone will be assessed using the Myoton Pro device, representing the natural oscillation frequency of the muscle at rest, and expressed in hertz (Hz).
Measured: Change in muscle tone after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Mechanical Stress Relaxation Time
Mechanical stress relaxation time will be assessed using the Myoton Pro device, representing the time required for the muscle to return to its original shape after a mechanical impulse, and expressed in milliseconds (ms).
Measured: Change in mechanical stress relaxation time after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Central and Peripheral Blood Pressure
Central and peripheral systolic and diastolic blood pressure will be measured using the SphygmoCor system and expressed in millimeters of mercury (mmHg).
Measured: Change in blood pressure from baseline (immediately before supplementation) to 12 weeks after the supplementation period.
Arterial stiffness
Arterial stiffness will be assessed using the SphygmoCor system by measuring carotid-femoral pulse wave velocity (PWV), expressed in meters per second (m/s).
Measured: Change in arterial stiffness from baseline (immediately before supplementation) to 12 weeks after the supplementation period.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2025
- Study startSep 2025 (estimated)
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- European University Cyprus
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Anastasios Theodorou, European University Cyprus
- Investigators
- Anastasios A Theodorou, Dr., Study chair, European University Cyprus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07134140
- Sponsor's protocol ID
- EUC omega-3
- Status last verified
- Aug 2025
- First submitted
- 10 Aug 2025
- Last updated
- 21 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) underlying the published results will be shared as supplementary files in accordance with the policies of each journal. Data sharing may vary across publications based on journal-specific requirements.
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Omega-3 Fatty Acid Supplementation on Muscle Performance, Neuromuscular Function, and Inflammation at Rest and Following Eccentric Exercise.
- ClinicalTrials.gov ID
- NCT07134140
- Acronym / sponsor ID
- EUC omega-3
- Conditions
- Healthy
- Keywords
- omega-3, eccentric exercise, muscle function
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 32 participants (estimated)
- Lead sponsor
- European University CyprusUniversity, hospital or other
- Study start
- Sep 2025 (estimated)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 21 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the effects of omega-3 fatty acid supplementation on muscle performance, neuromuscular function, inflammation, and oxidative stress at rest and after eccentric exercise. The findings may provide insights into the role of omega-3 fatty acids in muscle function, physiology, and metabolism following muscle-damaging exercise. Additionally, the effects of omega-3 fatty acids on cardiovascular health will be investigated.
Detailed description
The study is a double-blind, randomized controlled trial. Two parallel groups of 16 healthy males and females each (sex counterbalanced, 20-45 years) will randomly take 3 g of fish oil [1500 mg EPA (eicosapentaenoic acid) + 750 mg DHA (docosahexaenoic acid), Now Foods, USA] or a placebo (3 g of olive oil) for 12 weeks. Before taking the supplement, participants will perform a unilateral isokinetic eccentric exercise session of maximal voluntary intensity (10 repetitions x 10 sets of knee extensions at a speed of 60 degrees per second). Dominant and non-dominant legs will be allocated equally and randomly across participants. Physiological assessments and blood samples will be collected immediately before exercise and 2 and 4 days after eccentric exercise (bout 1). Then, participants will start the supplementation for 12 weeks. At the end of the supplementation period, participants will perform the same eccentric exercise protocol (bout 2) with their opposite leg. The same assessments and blood sampling will be conducted at the same time points (i.e., immediately before and 2 and 4 days after eccentric exercise).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Omega-3 | Experimental | Dietary Supplement: Omega-3Participants in this group will take 3 g of fish oil [(NOW, Ultra Omega-3 Fish Oil, (NOW, Bloomingdale, IL, USA)] for 12 weeks. |
| Placebo | Placebo comparator | Dietary Supplement: Placebo comparatorParticipants in this group will take 3 g of olive oil for 12 weeks. |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Body Mass Index (BMI) within the normal range (18.5-25 kg/m²).
- Healthy individuals without severe medical conditions (e.g., diabetes, coronary artery disease, hypertension, neuromuscular disorders).
- No musculoskeletal injury in the lower limbs (e.g., bone fracture, tendon rupture, grade III muscle strain) within the last 6 months before enrollment.
- Negative responses to all questions on the PAR-Q questionnaire indicating no contraindications to participating in exercise testing.
- Mentally capable of providing informed consent.
Key exclusion criteria (5 listed)
- Use of any pharmaceutical medications (e.g., statins, aspirin, ibuprofen).
- Use of dietary supplements (e.g., protein, vitamins) within the last 3 months before enrollment.
- Participation in a structured training program involving more than three training sessions per week during the study period.
- Following a special diet (e.g., intermittent fasting, ketogenic diet, vegetarian diet).
- Allergy or intolerance to fish oil or olive oil.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Omega-3Participants will take three capsules per day (a total of 1,500 mg EPA and 750 mg DHA). They will take 1 g with each main meal (breakfast, lunch, and dinner). | Dietary supplement | Omega-3 |
| Placebo comparatorParticipants will take 3 g of olive oil. They will take 1 g with each main meal (breakfast, lunch, and dinner). | Dietary supplement | Placebo |
Primary outcome
Muscle Strength
Time frame: Changes in muscle strength after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle strength of the knee extensors will be measured using an isokinetic dynamometer during maximal voluntary contractions. The unit of measure is Newton-meters (Nm).
Maximal Oxygen Uptake (VO₂ max)
Time frame: Changes in VO₂ max after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
VO₂ max will be assessed during a graded exercise test on a cycle ergometer. The measure unit is milliliters per kilogram of body mass per minute (ml/kg/min).
Muscle Fatigue Index (MFI)
Time frame: Changes in MFI after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
MFI will be calculated as the percentage decline (%) in peak torque across a series of repeated maximal contractions of the knee extensor muscles on an isokinetic dynamometer.
Muscle Oxygenation
Time frame: Changes in muscle oxygenation after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle oxygenation will be measured in the vastus lateralis using near-infrared spectroscopy (NIRS). Parameters include oxyhemoglobin (O₂Hb), deoxyhemoglobin (HHb), and total hemoglobin levels, which will be expressed in arbitrary units (AU).
Creatine Kinase
Time frame: Change in creatine kinase activity after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Creatine kinase activity will be measured in International Units (IU) via the enzymatic colorimetric method in fasting plasma samples.
Range of Motion (ROM)
Time frame: Change in ROM after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
ROM of the knee joint will be measured in degrees (°) using an isokinetic dynamometer, with full extension defined as 0° and flexion recorded up to 120°.
Muscle Thickness
Time frame: Change in muscle thickness after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle thickness of the vastus lateralis will be measured using B-mode ultrasound with a linear probe, in millimeters (mm).
Echo Intensity
Time frame: Change in echo intensity after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Echo intensity of the vastus lateralis will be assessed using B-mode ultrasound with a linear probe and quantified from grayscale image analysis, expressed in arbitrary units (0-255).
Blood Lipids Profile
Time frame: Change in blood lipids from baseline (immediately before supplementation) to 12 weeks after the supplementation period.
Fasting blood samples will be collected and analyzed to assess the participant's lipid profile, including: Total Cholesterol (TC). Expressed in mg/dL. Low-Density Lipoprotein Cholesterol (LDL-C). Expressed in mg/dL. High-Density Lipoprotein Cholesterol (HDL-C). Expressed in mg/dL. Triglycerides (TG). Expressed in mg/dL. Blood will be drawn after a minimum of 8-12 hours of fasting. Lipid concentrations will be determined using standard enzymatic colorimetric methods on an automated clinical chemistry analyzer.
21 secondary outcomes
Omega-3 Index
Time frame: Change in omega-3 index in red blood cells from baseline (immediately before supplementation) to 12 weeks after the supplementation period.
Rate of Force Development (RFD).
Time frame: Change in RFD after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Electromechanical Delay (EMD)
Time frame: Change in EMD after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Force Matching Error (FME)
Time frame: Change in FME after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Joint Position Sense (JPS)
Time frame: Change in JPS after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Delayed Onset Muscle Soreness (DOMS).
Time frame: Change in DOMS after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Countermovement Jump (CMJ)
Time frame: Change in CMJ after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Contact Time
Time frame: Change in contact time after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Stability Index
Time frame: Change in stability index after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
F2-Isoprostanes
Time frame: Change in F2-Isoprostanes after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Glutathione
Time frame: Change in glutathione after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Protein carbonyls
Time frame: Change in protein carbonyls after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Interleukin-6 (IL-6)
Time frame: Change in IL-6 after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Tumor Necrosis Factor-alpha (TNF-α)
Time frame: Change in TNF-α after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Pennation Angle
Time frame: Change in pennation angle after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Fascicle Length
Time frame: Change in fascile length after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle Stiffness
Time frame: Change in muscle stifness after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Muscle Tone
Time frame: Change in muscle tone after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Mechanical Stress Relaxation Time
Time frame: Change in mechanical stress relaxation time after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.
Central and Peripheral Blood Pressure
Time frame: Change in blood pressure from baseline (immediately before supplementation) to 12 weeks after the supplementation period.
Arterial stiffness
Time frame: Change in arterial stiffness from baseline (immediately before supplementation) to 12 weeks after the supplementation period.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2025.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) underlying the published results will be shared as supplementary files in accordance with the policies of each journal. Data sharing may vary across publications based on journal-specific requirements.
Related trials for Healthy
RecruitingPhase 3
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
Pneumococcal Disease
RecruitingObservational study
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
Mood Disorders, Anxiety Disorders
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
Not yet recruiting
Evaluating the Healthy Families PrEP Program for Women at Risk for HIV
HIV, Pregnancy
RecruitingPhase 1
A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.
Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Anastasios A Theodorou, Dr. study chair
European University Cyprus
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Omega-3 in people with Healthy, run by European University Cyprus at 1 site in Cyprus.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Cyprus. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anastasios A Theodorou, Dr (22713110, A.Theodorou@euc.ac.cy), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Muscle Strength (time frame: Changes in muscle strength after the first bout (week 0) and the second bout of exercise (week 12) from baseline (immediately before each bout) and at day 2 and day 4 after each exercise bout.). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2025.